Comparing the effectiveness of brolucizumab therapy alone versus that combined with subthreshold micropulse laser exposure in the treatment of diabetic macular edema

Background: Diabetic retinopathy (DR) is a major cause of blindness in working-age individuals the developed countries. Studies have found that diabetic macular edema (DME) visual impairment patients with diabetes mellitus (DM). Vascular endothelial growth factor (VEGF) plays an important role pathogenesis DME. Material and Methods: Eighty-two (153 eyes) DME were divided into two treatment groups. Group 1 (37 patients, 68 was treated injections anti-VEGF agent brolucizumab according to one plus pro re nata (PRN) regimen (once as needed) only, whereas group 2 (45 85 received combination “one PRN” therapy subthreshold micropulse laser exposure (SMPLE). Before after treatment, comprehensive ophthalmological examination performed, including best-corrected acuity (BCVA) height retinal central fovea assessed by optical coherence tomography. The parameters at 1, 3, 6 12 months treatment. Results: percentage no need for additional substantially higher combined than monotherapy (68.5% versus 12%, respectively, p <0.001). Conclusion: (intravitreal SMPLE) effective 68.5% cases within months. In this way, steady resorption accomplished through antivasoproliferative prolonged effects SMPLE session.